Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction

Asian Journal of Andrology

Volumn 8, Issue 2, 2006, Pages 219-224

  Perimenis, Petros ^a   Konstantinopoulos, A ^a   Perimeni, P P ^a   Gyftopoulos, K ^a   Kartsanis, G ^a   Liatsikos, E ^a   Athanasopoulos, A ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Diabetes mellitus; Erectile dysfunction; Impotence; Intracavernosal injections; Papaverine; Prostaglandin E1

Indexed keywords

PAPAVERINE; PROSTAGLANDIN E1; VASOACTIVE AGENT;

ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; ERECTILE DYSFUNCTION; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PENIS ERECTION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RIGIDITY; SELF INJECTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ALPROSTADIL; DIABETES COMPLICATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FOLLOW-UP STUDIES; HUMANS; IMPOTENCE; INJECTIONS; MALE; PAPAVERINE; PATIENT COMPLIANCE; PENILE ERECTION; PENIS; SELF ADMINISTRATION; VASODILATOR AGENTS;

EID: 33644796735     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1111/j.1745-7262.2006.00095.x     Document Type: Article

References (19)

1. Guay AT. Sexual dysfunction in the diabetic patient. Int J Impot Res 2001; 13: S47-50.
2. De Berardis G, Franciosi M, Belfiglio M, Di Nardo, B, Greenfield S, Kaplan SH, et al. Erectile dysfunction and quality of life in type 2 diabetic patients. A serious problem too often overlooked. Diabetes Care 2002; 25: 284-91.
3. Bemelmans BLH, Meuleman EJH, Doesburg WH, Notermans SLH, Debruyne FMJ. Erectile dysfunction in diabetic men: The neurological factor revisited. J Urol 1994; 151: 884-9.
4. Veves A, Webster L, Chen TF, Payne S, Boulton AJM. Aetiopathogenesis and management of impotence in diabetic males: Four years experience from a combined clinic. Diabetic Med 1995; 12: 77-82.
5. Heaton JP, Lording D, Liu SN, Litonjua AD, Guangwei L, Kim SC, et al. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res 2001; 13: 317-21.
6. Vickers MA, Satyanarayana R. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. Int J Impot Res 2002; 14: 466-71.
7. Zhu GY, Shen Y. Application of pudental evoked potentials in diagnosis of erectile dysfunction. Asian J Androl 1999; 1: 145-50.
8. Xu ZS, Fu Q, Zhao ST, Liu HN. Effect of diabetes and insulin treatment on nitric oxide synthase content in rat corpus cavernosum. Asian J Androl 2001; 3: 139-42.
9. Bancroft J, Gutierrez P. Erectile dysfunction in men with and without diabetes mellitus: A comparative study. Diabetic Med 1996; 13: 84-9.
10. Perimenis P, Gyftopoulos K, Athanasopoulos A, Barbalias G. Diabetic impotence treated by intracavernosal injections: High treatment compliance and increasing dosage of vaso-active drugs. Eur Urol 2001; 40: 398-403.
11. Althof SE, Turner LA, Levine SB, Risen C, Kursh E, Bodner D, et al. Why do so many people drop out from auto-injection therapy for impotence? J Sex Marital Ther 1989; 15: 121-9.
12. Markou S, Perimenis P, Gyftopoulos K, Athanasopoulos A, Barbalias G. Vardenafil (Levitra) for erectile dysfunction: A systematic review and meta-analysis of clinical trial reports. Int J Impot Res 2004; 16: 470-8.
13. Perimenis P, Athanasopoulos A, Geramoutsos I, Barbalias G. The incidence of pharmacologically induced priapism in the diagnostic and therapeutic management of 685 men with erectile dysfunction. Urol Int 2001; 66: 22-6.
14. Aversa A, Fabbri A. New oral agents for erectile dysfunction: What is changing in our practice? Asian J Androl 2001; 3: 175-9.
15. Perimenis P, Markou S, Gyftopoulos K, Athanasopoulos A, Giannitsas K, Barbalias G. Switching from long-term treatment with self-injections to oral sildenafil in diabetic patients with severe erectile dysfunction. Eur Urol 2002; 41: 387-91.
16. Wespes E, Sattar AA, Noel JC, Schulman CC. Does prostaglandin E1 therapy modify the intracavernous musculature? J Urol 2000; 163: 464-6.
17. Shi JP, Zhao YM, Song YT. Effect of aging on expression of nitric oxide synthase I and activity of nitric oxide synthase in rat penis. Asian J Androl 2003; 5: 117-20.
18. Lu YL, Shen ZJ, Wang H, Chen SW, Zhou XL, Chen ZD. Ultrastructural changes of penile tunica albuginea in diabetic rats. Asian J Androl 2004; 6: 365-8.
19. Bechara A, Casabe A, Cheliz G, Romano S, Fredotovich N. Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses. J Urol 1996; 155: 913-4.